Stoke Therapeutics (STOK) Receivables (2024 - 2026)

Stoke Therapeutics' Receivables history runs 3 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• On a quarterly basis, Receivables changed N/A year-over-year to $6.1 million in Q1 2026; TTM through Mar 2026 was $6.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $7.9 million, up 233.83% from the prior year.
• Receivables fell to $6.1 million in Q1 2026 per STOK's latest filing, from $7.9 million in the prior quarter.
• Across five years, Receivables topped out at $10.8 million in Q3 2025 and bottomed at $2.4 million in Q4 2024.
• The 3-year median for Receivables is $7.0 million (2025), against an average of $6.8 million.
• Biggest YoY gain for Receivables was 233.83% in 2025; the steepest drop was 233.83% in 2025.
• Year by year, Receivables stood at $2.4 million in 2024, then jumped by 233.83% to $7.9 million in 2025, then dropped by 22.31% to $6.1 million in 2026.
• Per Business Quant, the three latest STOK Receivables figures stand at $6.1 million (Q1 2026), $7.9 million (Q4 2025), and $10.8 million (Q3 2025).